{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T20:04:06Z","timestamp":1785528246676,"version":"3.56.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Urol Rep"],"DOI":"10.1007\/s11934-026-01348-x","type":"journal-article","created":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T05:02:19Z","timestamp":1785214939000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Surgical Management of PSMA PET-Positive Lymph Nodes in Prostate Cancer"],"prefix":"10.1007","volume":"27","author":[{"given":"Andrea","family":"Cosenza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo","family":"Quarta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armando","family":"Galdieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Brancaccio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Occhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Elena","family":"Porzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Zaurito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Viti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfonso","family":"Santangelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Scilipoti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Scuderi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Barletta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armando","family":"Stabile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Montorsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Briganti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Gandaglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,28]]},"reference":[{"key":"1348_CR1","unstructured":"EAU Guidelines. Edn. presented at the EAU Annual Congress London 2026. ISBN 978-94-92671-32-5."},{"key":"1348_CR2","doi-asserted-by":"publisher","unstructured":"Bianchi L, Droghetti M, Catanzaro C et al. Prostate-specific membrane antigen positron emission tomography versus conventional imaging for preoperative staging high-risk prostate cancer patients undergoing surgery for cN0M0 disease: An European association of urology\u2014young academic urologists prostate cancer working group multi-institutional study. Eur Urol Oncol. Published online December 2025. https:\/\/doi.org\/10.1016\/j.euo.2025.11.011","DOI":"10.1016\/j.euo.2025.11.011"},{"issue":"10231","key":"1348_CR3","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","volume":"395","author":"MS Hofman","year":"2020","unstructured":"Hofman MS, Lawrentschuk N, Francis RJ, et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet. 2020;395(10231):1208\u201316. https:\/\/doi.org\/10.1016\/S0140-6736(20)30314-7.","journal-title":"Lancet"},{"issue":"1","key":"1348_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.euo.2021.08.001","volume":"5","author":"A Stabile","year":"2022","unstructured":"Stabile A, Pellegrino A, Mazzone E, et al. Can negative prostate-specific membrane antigen positron emission tomography\/computed tomography avoid the need for pelvic lymph node dissection in newly diagnosed prostate cancer patients? A systematic review and meta-analysis with backup histology as reference standard. Eur Urol Oncol. 2022;5(1):1\u201317. https:\/\/doi.org\/10.1016\/j.euo.2021.08.001.","journal-title":"Eur Urol Oncol"},{"issue":"6","key":"1348_CR5","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1016\/j.eururo.2025.03.003","volume":"87","author":"E Mazzone","year":"2025","unstructured":"Mazzone E, Cannoletta D, Quarta L, et al. A comprehensive systematic review and meta-analysis of the role of prostate-specific membrane antigen positron emission tomography for prostate cancer diagnosis and primary staging before definitive treatment. Eur Urol. 2025;87(6):654\u201371. https:\/\/doi.org\/10.1016\/j.eururo.2025.03.003.","journal-title":"Eur Urol"},{"issue":"4","key":"1348_CR6","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.eururo.2022.06.002","volume":"82","author":"G Gandaglia","year":"2022","unstructured":"Gandaglia G, Mazzone E, Stabile A, et al. Prostate-specific membrane antigen radioguided surgery to detect nodal metastases in primary prostate cancer patients undergoing robot-assisted radical prostatectomy and extended pelvic lymph node dissection: Results of a planned interim analysis of a prospective phase 2 study. Eur Urol. 2022;82(4):411\u20138. https:\/\/doi.org\/10.1016\/j.eururo.2022.06.002.","journal-title":"Eur Urol"},{"key":"1348_CR7","doi-asserted-by":"publisher","unstructured":"Barletta F, Moro FD, Rajwa P, et al. MP14-01 rates and predictors of false node-positive PSMA-pet in patients treated with radical prostatectomy and extend pelvic lymph-node dissection: Results from a large, multi-institutional database. Journal of Urology. 2024;211(5S). https:\/\/doi.org\/10.1097\/01.JU.0001009428.69695.82.01","DOI":"10.1097\/01.JU.0001009428.69695.82.01"},{"issue":"3","key":"1348_CR8","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/J.EURURO.2025.08.005","volume":"89","author":"K Herrmann","year":"2026","unstructured":"Herrmann K, Walz J, MacLennan S, et al. SPARC: The standardised prostate-specific membrane antigen positron emission tomography\/computed tomography analysis and reporting consensus: A delphi analysis. Eur Urol. 2026;89(3):260\u201374. https:\/\/doi.org\/10.1016\/J.EURURO.2025.08.005.","journal-title":"Eur Urol"},{"issue":"5","key":"1348_CR9","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.eururo.2023.02.002","volume":"83","author":"R Seifert","year":"2023","unstructured":"Seifert R, Emmett L, Rowe SP, et al. Second version of the prostate cancer molecular imaging standardized evaluation framework including response evaluation for clinical trials (PROMISE V2). Eur Urol. 2023;83(5):405\u201312. https:\/\/doi.org\/10.1016\/j.eururo.2023.02.002.","journal-title":"Eur Urol"},{"issue":"5","key":"1348_CR10","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1016\/j.euo.2025.08.005","volume":"8","author":"F Kleiburg","year":"2025","unstructured":"Kleiburg F, Dirix P, Fonteyne V, et al. Stage migration on prostate-specific membrane antigen positron emission tomography\/computed tomography in comparison to conventional imaging in patients with high-risk prostate cancer referred for radiation therapy: Results from the phase 2\/3 THUNDER Trial. Eur Urol Oncol. 2025;8(5):1333\u20139. https:\/\/doi.org\/10.1016\/j.euo.2025.08.005.","journal-title":"Eur Urol Oncol"},{"issue":"1","key":"1348_CR11","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.juro.2007.08.125","volume":"179","author":"ON Gofrit","year":"2008","unstructured":"Gofrit ON, Zorn KC, Steinberg GD, Zagaja GP, Shalhav AL. The will rogers phenomenon in urological oncology. J Urol. 2008;179(1):28\u201333. https:\/\/doi.org\/10.1016\/j.juro.2007.08.125.","journal-title":"J Urol"},{"key":"1348_CR12","unstructured":"Spratt DE, An Y, Bitting R et al. NCCN guidelines version 5.2026 prostate cancer nccn guidelines panel disclosures. 2026. https:\/\/www.nccn.org\/home\/"},{"key":"1348_CR13","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/S0140-6736(21)02437-5","volume":"399","author":"G Attard","year":"2022","unstructured":"Attard G, Murphy L, Clarke NW, et al. Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol. Lancet. 2022;399:447\u201360. https:\/\/doi.org\/10.1016\/S0140-6736(21)02437-5.","journal-title":"Lancet"},{"issue":"6","key":"1348_CR14","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1016\/j.euo.2024.05.016","volume":"7","author":"D Milonas","year":"2024","unstructured":"Milonas D, Giesen A, Laenen A, et al. Effect of radical prostatectomy on survival for men with high-risk nonmetastatic prostate cancer features selected according to STAMPEDE criteria: An EMPaCT study. Eur Urol Oncol. 2024;7(6):1478\u201386. https:\/\/doi.org\/10.1016\/j.euo.2024.05.016.","journal-title":"Eur Urol Oncol"},{"key":"1348_CR15","doi-asserted-by":"publisher","unstructured":"Methley AM, Campbell S, Chew-Graham C, McNally R, Cheraghi-Sohi S, PICO. PICOS and SPIDER: A comparison study of specificity and sensitivity in three search tools for qualitative systematic reviews. BMC Health Serv Res. 2014;14(1). https:\/\/doi.org\/10.1186\/s12913-014-0579-0.","DOI":"10.1186\/s12913-014-0579-0"},{"issue":"1","key":"1348_CR16","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.eururo.2023.03.001","volume":"84","author":"KM Chow","year":"2023","unstructured":"Chow KM, So WZ, Lee HJ, et al. Head-to-head comparison of the diagnostic accuracy of prostate-specific membrane antigen positron emission tomography and conventional imaging modalities for initial staging of intermediate- to high-risk prostate cancer: A systematic review and meta-analysis. Eur Urol. 2023;84(1):36\u201348. https:\/\/doi.org\/10.1016\/j.eururo.2023.03.001.","journal-title":"Eur Urol"},{"issue":"11","key":"1348_CR17","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1001\/jamaoncol.2021.3771","volume":"7","author":"TA Hope","year":"2021","unstructured":"Hope TA, Eiber M, Armstrong WR, et al. Diagnostic accuracy of 68Ga-PSMA-11 PET for pelvic nodal metastasis detection prior to radical prostatectomy and pelvic lymph node dissection: A multicenter prospective phase 3 imaging trial. JAMA Oncol. 2021;7(11):1635\u201342. https:\/\/doi.org\/10.1001\/jamaoncol.2021.3771.","journal-title":"JAMA Oncol"},{"issue":"4","key":"1348_CR18","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.euf.2025.01.015","volume":"11","author":"RB Incesu","year":"2025","unstructured":"Incesu RB, Preisser F, Pompe RS, et al. Diagnostic accuracy of prostate-specific membrane antigen positron emission tomography\/computed tomography for primary lymph node staging before radical prostatectomy. Eur Urol Focus. 2025;11(4):582\u20137. https:\/\/doi.org\/10.1016\/j.euf.2025.01.015.","journal-title":"Eur Urol Focus"},{"key":"1348_CR19","doi-asserted-by":"publisher","unstructured":"Hofman MS, Kasivisvanathan V, Link E et al. Baseline nodal status on 68Ga-PSMA-11 positron emission tomography\/computed tomography in men with intermediate- to high-risk prostate cancer is prognostic for treatment failure: Follow-up of the proPSMA Trial. Eur Urol Oncol. Published online 2024. https:\/\/doi.org\/10.1016\/j.euo.2024.11.006","DOI":"10.1016\/j.euo.2024.11.006"},{"key":"1348_CR20","doi-asserted-by":"publisher","DOI":"10.1111\/bju.70280","author":"NA Pickersgill","year":"2026","unstructured":"Pickersgill NA, Yu R, Vertosick EA, et al. Diagnostic and prognostic utility of PSMA-PET\/CT in node-metastatic prostate cancer. BJU Int Published online. 2026. https:\/\/doi.org\/10.1111\/bju.70280.","journal-title":"BJU Int Published online"},{"issue":"2","key":"1348_CR21","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.clgc.2023.11.006","volume":"22","author":"G Marra","year":"2024","unstructured":"Marra G, Rajwa P, Filippini C, et al. The prognostic role of preoperative PSMA PET\/CT in cN0M0 pN+ prostate cancer: A multicenter study. Clin Genitourin Cancer. 2024;22(2):244\u201351. https:\/\/doi.org\/10.1016\/j.clgc.2023.11.006.","journal-title":"Clin Genitourin Cancer"},{"key":"1348_CR22","doi-asserted-by":"publisher","DOI":"10.1111\/bju.70293","author":"AS Bruins Slot","year":"2026","unstructured":"Bruins Slot AS, Sweere V, Heetman JG, et al. Nodal maximum standardised uptake value improves PSMA-PET\/CT-based nodal staging in intermediate- and high-risk prostate cancer. BJU Int Published online. 2026. https:\/\/doi.org\/10.1111\/bju.70293.","journal-title":"BJU Int Published online"},{"issue":"1","key":"1348_CR23","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.eururo.2016.12.003","volume":"72","author":"N Fossati","year":"2017","unstructured":"Fossati N, Willemse PPM, Van den Broeck T, et al. The benefits and harms of different extents of lymph node dissection during radical prostatectomy for prostate cancer: A systematic review. Eur Urol. 2017;72(1):84\u2013109. https:\/\/doi.org\/10.1016\/j.eururo.2016.12.003.","journal-title":"Eur Urol"},{"issue":"6","key":"1348_CR24","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/j.eururo.2025.03.004","volume":"87","author":"MJ Roberts","year":"2025","unstructured":"Roberts MJ, Gandaglia G, Oprea-Lager DE, Stranne J, Cornford P, Tilki D. Pelvic lymph node dissection in prostate cancer: Evidence and implications. Eur Urol. 2025;87(6):619\u201321. https:\/\/doi.org\/10.1016\/j.eururo.2025.03.004.","journal-title":"Eur Urol"},{"issue":"5","key":"1348_CR25","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.eururo.2020.11.040","volume":"79","author":"JFP Lestingi","year":"2021","unstructured":"Lestingi JFP, Guglielmetti GB, Trinh QD, et al. Extended versus limited pelvic lymph node dissection during radical prostatectomy for intermediate- and high-risk prostate cancer: Early oncological outcomes from a randomized phase 3 trial. Eur Urol. 2021;79(5):595\u2013604. https:\/\/doi.org\/10.1016\/j.eururo.2020.11.040.","journal-title":"Eur Urol"},{"issue":"2","key":"1348_CR26","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.eururo.2024.10.006","volume":"87","author":"KA Touijer","year":"2025","unstructured":"Touijer KA, Vertosick EA, Sjoberg DD, et al. Pelvic lymph node dissection in prostate cancer: Update from a randomized clinical trial of limited versus extended dissection. Eur Urol. 2025;87(2):253\u201360. https:\/\/doi.org\/10.1016\/j.eururo.2024.10.006.","journal-title":"Eur Urol"},{"issue":"1","key":"1348_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.euo.2021.08.001","volume":"5","author":"A Stabile","year":"2022","unstructured":"Stabile A, Pellegrino A, Mazzone E, et al. Can negative prostate-specific membrane antigen positron emission tomography\/computed tomography avoid the need for pelvic lymph node dissection in newly diagnosed prostate cancer patients? A systematic review and meta-analysis with backup histology as reference standard. Eur Urol Oncol. 2022;5(1):1\u201317. https:\/\/doi.org\/10.1016\/j.euo.2021.08.001.","journal-title":"Eur Urol Oncol"},{"issue":"4","key":"1348_CR28","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1038\/s41391-024-00930-z","volume":"28","author":"RB Incesu","year":"2025","unstructured":"Incesu RB, Preisser F, Nohe F, Maurer T, Graefen M, Tilki D. Negative PSMA PET can be used to avoid unnecessary pelvic lymph node dissection in intermediate risk prostate cancer. Prostate Cancer Prostatic Dis. 2025;28(4):874\u20138. https:\/\/doi.org\/10.1038\/s41391-024-00930-z.","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"8","key":"1348_CR29","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1002\/pros.24884","volume":"85","author":"B Esen","year":"2025","unstructured":"Esen B, Seymen H, Armutlu A, et al. Impact of pelvic lymph node dissection on early oncological outcomes in intermediate-risk prostate cancer patients with node-negative PSMA PET. Prostate. 2025;85(8):777\u201383. https:\/\/doi.org\/10.1002\/pros.24884.","journal-title":"Prostate"},{"issue":"4","key":"1348_CR30","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1097\/JU.0000000000004659","volume":"214","author":"A Eraky","year":"2025","unstructured":"Eraky A, Tillu N, Ben-David R, et al. Diagnostic accuracy of [18F]-DCFPyL prostate-specific membrane antigen positron emission tomography\/computerized tomography in intermediate-risk prostate cancer undergoing radical prostatectomy: Is pelvic lymph node dissection still necessary? J Urol. 2025;214(4):365\u201373. https:\/\/doi.org\/10.1097\/JU.0000000000004659.","journal-title":"J Urol"},{"issue":"3","key":"1348_CR31","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1111\/bju.14828","volume":"124","author":"JW Yaxley","year":"2019","unstructured":"Yaxley JW, Raveenthiran S, Nouhaud FX, et al. Risk of metastatic disease on 68gallium-prostate-specific membrane antigen positron emission tomography\/computed tomography scan for primary staging of 1253 men at the diagnosis of prostate cancer. BJU Int. 2019;124(3):401\u20137. https:\/\/doi.org\/10.1111\/bju.14828.","journal-title":"BJU Int"},{"issue":"2","key":"1348_CR32","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.eururo.2021.05.006","volume":"80","author":"D Meijer","year":"2021","unstructured":"Meijer D, van Leeuwen PJ, Roberts MJ, et al. External validation and addition of prostate-specific membrane antigen positron emission tomography to the most frequently used nomograms for the prediction of pelvic lymph-node metastases: an international multicenter study. Eur Urol. 2021;80(2):234\u201342. https:\/\/doi.org\/10.1016\/j.eururo.2021.05.006.","journal-title":"Eur Urol"},{"key":"1348_CR33","doi-asserted-by":"publisher","unstructured":"Gandaglia G, Barletta F, Scuderi S et al. External validation of nomograms for the identification of pelvic nodal dissection candidates among prostate cancer patients with negative preoperative prostate-specific membrane antigen positron emission tomography. Eur Urol Oncol. Published online February 2025. https:\/\/doi.org\/10.1016\/j.euo.2025.01.004","DOI":"10.1016\/j.euo.2025.01.004"},{"issue":"10","key":"1348_CR34","doi-asserted-by":"publisher","first-page":"3744","DOI":"10.1007\/s00259-025-07241-y","volume":"52","author":"TD Van Bergen","year":"2025","unstructured":"Van Bergen TD, Braat AJAT, Hermsen R, et al. External validation of nomograms including PSMA PET information for the prediction of lymph node involvement of prostate cancer. Eur J Nucl Med Mol Imaging. 2025;52(10):3744\u201356. https:\/\/doi.org\/10.1007\/s00259-025-07241-y.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5","key":"1348_CR35","doi-asserted-by":"publisher","first-page":"639","DOI":"10.23736\/S2724-6051.25.06470-5","volume":"77","author":"M Bauckneht","year":"2025","unstructured":"Bauckneht M, Checcucci E, Lanfranchi F, et al. The added value of PSMA PET to nomograms in identifying optimal candidates for extended pelvic lymph node dissection in intermediate-risk prostate cancer patients. Minerva Urol Nephrol. 2025;77(5):639\u201346. https:\/\/doi.org\/10.23736\/S2724-6051.25.06470-5.","journal-title":"Minerva Urol Nephrol"},{"key":"1348_CR36","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.euros.2025.12.003","volume":"83","author":"F Zattoni","year":"2026","unstructured":"Zattoni F, Rajwa P, Kasivisvanathan V, et al. Impact of negative prostate-specific membrane antigen positron emission tomography on the decision to perform a pelvic lymph node dissection during radical prostatectomy for intermediate- to high-risk prostate cancer patients: Results of an international survey. Eur Urol Open Sci. 2026;83:142\u201351. https:\/\/doi.org\/10.1016\/j.euros.2025.12.003.","journal-title":"Eur Urol Open Sci"},{"key":"1348_CR37","unstructured":"Z\u00fcrich Triemli S. A0642 DISSECTION 2.0 extended pelvic lymph node dissection vs. no pelvic lymph node dissection at radical prostatectomy in PSMA PET negative staged men: A multicenter, randomized phase III trial."},{"issue":"3","key":"1348_CR38","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.euo.2023.09.002","volume":"7","author":"CYL Yaow","year":"2024","unstructured":"Yaow CYL, Lee HJ, Teoh SE, et al. Local therapy on clinically lymph node-positive prostate cancer: A systematic review and meta-analysis. Eur Urol Oncol. 2024;7(3):355\u201364. https:\/\/doi.org\/10.1016\/j.euo.2023.09.002.","journal-title":"Eur Urol Oncol"},{"issue":"5","key":"1348_CR39","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/j.eururo.2018.10.042","volume":"75","author":"G Gandaglia","year":"2019","unstructured":"Gandaglia G, Soligo M, Battaglia A, et al. Which patients with clinically node-positive prostate cancer should be considered for radical prostatectomy as part of multimodal treatment? The impact of nodal burden on long-term outcomes. Eur Urol. 2019;75(5):817\u201325. https:\/\/doi.org\/10.1016\/j.eururo.2018.10.042.","journal-title":"Eur Urol"},{"issue":"2","key":"1348_CR40","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.euo.2023.08.010","volume":"7","author":"E Mazzone","year":"2024","unstructured":"Mazzone E, Gandaglia G, Robesti D, et al. Which patients with prostate cancer and lymph node uptake at preoperative prostate-specific membrane antigen positron emission tomography\/computerized tomography scan are at a higher risk of prostate-specific antigen persistence after radical prostatectomy? Identifying indicators of systemic disease by integrating clinical, magnetic resonance imaging, and functional imaging parameters. Eur Urol Oncol. 2024;7(2):231\u201340. https:\/\/doi.org\/10.1016\/j.euo.2023.08.010.","journal-title":"Eur Urol Oncol"},{"issue":"3","key":"1348_CR41","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1111\/bju.15881","volume":"131","author":"D Meijer","year":"2023","unstructured":"Meijer D, Ettema RH, van Leeuwen PJ, et al. The prognostic value of lymph node staging with prostate-specific membrane antigen (PSMA) positron emission tomography\/computed tomography (PET\/CT) and extended pelvic lymph node dissection in node-positive patients with prostate cancer. BJU Int. 2023;131(3):330\u20138. https:\/\/doi.org\/10.1111\/bju.15881.","journal-title":"BJU Int"},{"issue":"3","key":"1348_CR42","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1038\/s41391-021-00347-y","volume":"24","author":"S Dekalo","year":"2021","unstructured":"Dekalo S, Kuten J, Mintz I, et al. Preoperative 68Ga-PSMA PET\/CT defines a subgroup of high-risk prostate cancer patients with favorable outcomes after radical prostatectomy and lymph node dissection. Prostate Cancer Prostatic Dis. 2021;24(3):910\u20136. https:\/\/doi.org\/10.1038\/s41391-021-00347-y.","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"1","key":"1348_CR43","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1002\/pros.24627","volume":"84","author":"P Rajwa","year":"2024","unstructured":"Rajwa P, Heidenreich J, Drzezga A, Schmidt M, Shariat SF, Heidenreich A. The diagnostic accuracy of 68Ga-PSMA-PET\/CT in primary staging of patients with high-risk nonmetastatic prostate cancer treated with radical prostatectomy: A single-center cohort analysis. Prostate. 2024;84(1):74\u20138. https:\/\/doi.org\/10.1002\/pros.24627.","journal-title":"Prostate"},{"issue":"11","key":"1348_CR44","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.2967\/JNUMED.121.263743","volume":"63","author":"W Gondoputro","year":"2022","unstructured":"Gondoputro W, Scheltema MJ, Blazevski A, et al. Robot-assisted prostate-specific membrane antigen-radioguided surgery in primary diagnosed prostate cancer. J Nucl Med. 2022;63(11):1659\u201364. https:\/\/doi.org\/10.2967\/JNUMED.121.263743.","journal-title":"J Nucl Med"},{"issue":"12","key":"1348_CR45","doi-asserted-by":"publisher","first-page":"3789","DOI":"10.1007\/s00259-024-06789-5","volume":"51","author":"L Quarta","year":"2024","unstructured":"Quarta L, Mazzone E, Cannoletta D, et al. Defining the optimal target-to-background ratio to identify positive lymph nodes in prostate cancer patients undergoing robot-assisted [99mTc]Tc-PSMA radioguided surgery: updated results and ad interim analyses of a prospective phase II study. Eur J Nucl Med Mol Imaging. 2024;51(12):3789\u201398. https:\/\/doi.org\/10.1007\/s00259-024-06789-5.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"1348_CR46","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.euo.2022.12.001","volume":"6","author":"L Lunger","year":"2023","unstructured":"Lunger L, Steinhelfer L, Korn P, et al. Prostate-specific membrane antigen-radioguided surgery facilitates pelvic lymph node dissection during radical prostatectomy for the treatment of locally advanced prostate cancer with regional lymph node metastases. Eur Urol Oncol. 2023;6(1):95\u20138. https:\/\/doi.org\/10.1016\/j.euo.2022.12.001.","journal-title":"Eur Urol Oncol"},{"key":"1348_CR47","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.euros.2025.10.018","volume":"82","author":"P Korn","year":"2025","unstructured":"Korn P, Lischewski F, Staehler H, et al. Radical prostatectomy combined with prostate specific membrane antigen\u2013radioguided lymph node dissection is associated with longer treatment-free survival for patients with primary lymph node\u2013positive prostate cancer. Eur Urol Open Sci. 2025;82:201\u20137. https:\/\/doi.org\/10.1016\/j.euros.2025.10.018.","journal-title":"Eur Urol Open Sci"},{"issue":"1","key":"1348_CR48","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.euf.2025.05.003","volume":"11","author":"L Quarta","year":"2025","unstructured":"Quarta L, Stabile A, Chiti A, Montorsi F, Briganti A, Gandaglia G. Radioguided surgery for prostate cancer. Eur Urol Focus. Elsevier B V. 2025;11(1):29\u201332. https:\/\/doi.org\/10.1016\/j.euf.2025.05.003.","journal-title":"Elsevier B V"},{"key":"1348_CR49","doi-asserted-by":"publisher","unstructured":"Quarta L, Cannoletta D, Pellegrino F, et al. The role of robot-assisted, imaging-guided surgery in prostate cancer patients. Cancers (Basel). Multidisciplinary Digit Publishing Inst (MDPI). 2025;17(9). https:\/\/doi.org\/10.3390\/cancers17091401.","DOI":"10.3390\/cancers17091401"}],"container-title":["Current Urology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11934-026-01348-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11934-026-01348-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11934-026-01348-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T18:19:26Z","timestamp":1785521966000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11934-026-01348-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,28]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1348"],"URL":"https:\/\/doi.org\/10.1007\/s11934-026-01348-x","relation":{},"ISSN":["1534-6285"],"issn-type":[{"value":"1534-6285","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,28]]},"assertion":[{"value":"6 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":1,"name":"Ethics","label":"Human and Animal Rights","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing Interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. All tables are original and were created by the authors specifically for this manuscript. They have not been previously published or adapted from other sources.","order":3,"name":"Ethics","label":"Table Permissions","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"34"}}